

Prof. Dr. med. Dirk Jäger

(* 1964)

National Center for Tumor Diseases,
University Hospital Heidelberg
Medical Oncology
Director Medical Oncology
Im Neuenheimer Feld 350
69120 Heidelberg



Curriculum vitae

- 1998-2000 Postdoctoral Fellowship (Cancer Research Institute) Cornell Medical Center: Identification and characterization of tumor-associated antigens in melanoma and breast cancer using the SEREX approach (Y.T. Chen)
- 2000-2003 Group leader of the Antigen Discovery Program at Krankenhaus Nordwest, Frankfurt (Director: Alexander Knuth)
- 2003-2005 Attending Physician at the Department of Oncology, University Hospital Zurich, Switzerland (Director: Alexander Knuth) Leader of the Laboratory for Tumor Immunology, Coordinator of the Clinical Trials Center Zurich as part of the Ludwig Institute for Cancer Research
- 2005 Director of the Medical Oncology Department, National Center for Tumor Diseases, University Hospital Heidelberg
- 2006 Official Affiliation with the Ludwig Institute for Cancer Research

Activities in the scientific community, honors, awards

Rose-Marie-Finnell Memorial Fellowship for Breast Cancer Research (1998); Since 2000 Member of the Antigen Discovery Program, Cancer Research Institute, New York and Ludwig Institute for Cancer Research, New York; AVON Award for breast cancer research, Cancer Research Institute, NY, 2001; Investigators Award, Cancer Research Institute, New York, 2006.

Research fields

Analysis of spontaneous interactions of the immune system with developing tumors. Identification and characterization of tumor-associated antigens in different tumor types as potential targets for immunotherapy approaches using a serological cloning strategy (SEREX). Characterization of tumor-associated antigens and validation for T-cell based as well as antibody based therapies.

Functional characterization of tumor associated antigens: implications for therapeutic strategies. Evaluation of potential target antigens in clinical trials (antibodies, vaccines).

Analysis of spontaneous humoral and cellular immune responses in cancer patients as potential prognostic and diagnostic markers in different tumor types.

Selected publications

- Jäger, E., Karbach, J., Gnjatic, S., Neumann, A., Bender, A., Valmori, D., Ayyoub, M., Ritter, E., Ritter, G., Jäger, D., Panicali, D., Hoffman, E., Pan, L., Oettgen, H., Old, L. J., and Knuth, A. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. *Proc Natl Acad Sci U S A*, 103: 14453-14458, 2006.
- Walton, S. M., Gerlinger, M., de la Rosa, O., Nuber, N., Knights, A., Gati, A., Laumer, M., Strauss, L., Exner, C., Schafer, N., Urošević, M., Dummer, R., Tiercy, J. M., Mackensen, A., Jaeger, E., Levy, F., Knuth, A., Jäger, D., and Zippelius, A. Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients. *J Immunol*, 177: 8212-8218, 2006.
- Varga Z, Theurillat JP, Filonenko V, Sasse B, Odermatt B, Jungbluth AA, Chen YT, Old, LJ, Knuth A, Jäger D,* Moch H (2006). Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases. *Clin Cancer Res* 12, 2745-2751 [* shared senior authorship]
- Jäger D, Stockert E, Gure AO, Scanlan MJ, Karbach J, Jäger E, Knuth A, Old LJ, Chen YT (2001). Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. *Cancer Res* 61, 2055-2061
- Robbiani DF, Finch RA, Jäger D, Müller WA, Sartorelli AC, Randolph GJ (2000). The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. *Cell* 103, 757-768
- Jäger D, Stockert E, Jäger E, Gure AO, Scanlan MJ, Knuth A, Old LJ, Chen YT (2000). Serological cloning of a melanocyte rab guanosine 5'-triphosphate-binding protein and a chromosome condensation protein from a melanoma complementary DNA library. *Cancer Res* 60, 3584-3591